See more : Basellandschaftliche Kantonalbank (BLKB.SW) Income Statement Analysis – Financial Results
Complete financial analysis of BioLargo, Inc. (BLGO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioLargo, Inc., a leading company in the Chemicals industry within the Basic Materials sector.
You may be interested
- American Resources Corporation (AREC) Income Statement Analysis – Financial Results
- Insimbi Industrial Holdings Limited (ISB.JO) Income Statement Analysis – Financial Results
- Verano Holdings Corp. (VRNOF) Income Statement Analysis – Financial Results
- Bermaz Auto Berhad (5248.KL) Income Statement Analysis – Financial Results
- Direct Selling Acquisition Corp. (DSAQW) Income Statement Analysis – Financial Results
BioLargo, Inc. (BLGO)
About BioLargo, Inc.
BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.23M | 5.88M | 2.53M | 2.43M | 1.86M | 1.36M | 516.21K | 281.11K | 127.58K | 111.55K | 167.95K | 65.54K | 156.19K | 156.76K | 138.13K | 0.00 | 80.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 749.84K | 833.54K | 1.88M | 2.39M | 1.93M | 2.50M | 1.30M | 4.50M | 7.70M | 9.40M | 9.80M | 6.70M |
| Cost of Revenue | 6.08M | 3.03M | 1.43M | 1.20M | 945.00K | 743.00K | 322.72K | 105.88K | 62.07K | 56.00K | 29.66K | 39.78K | 44.76K | 125.48K | 114.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.29K | 0.00 | 119.41K | 119.18K | 22.41K | 0.00 | 0.00 | 0.00 | 0.00 | 5.10M | 6.40M | 7.80M | 7.70M | 5.20M |
| Gross Profit | 6.15M | 2.86M | 1.10M | 1.23M | 916.00K | 621.00K | 193.50K | 175.23K | 65.52K | 55.55K | 138.29K | 25.76K | 111.43K | 31.28K | 23.58K | 0.00 | 80.00K | 0.00 | 0.00 | 0.00 | -20.29K | 0.00 | 630.43K | 714.35K | 1.86M | 2.39M | 1.93M | 2.50M | 1.30M | -600.00K | 1.30M | 1.60M | 2.10M | 1.50M |
| Gross Profit Ratio | 50.32% | 48.56% | 43.58% | 50.49% | 49.22% | 45.53% | 37.48% | 62.34% | 51.35% | 49.80% | 82.34% | 39.30% | 71.34% | 19.95% | 17.07% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 84.08% | 85.70% | 98.81% | 100.00% | 100.00% | 100.00% | 100.00% | -13.33% | 16.88% | 17.02% | 21.43% | 22.39% |
| Research & Development | 2.28M | 1.32M | 1.37M | 1.34M | 1.47M | 1.72M | 1.63M | 1.38M | 684.55K | 642.92K | 742.25K | 126.02K | 99.50K | 100.56K | 170.12K | 113.75K | 131.35K | 129.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 6.14M | 5.26M | 4.43M | 0.00 | 3.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.97M | 2.60M | 1.77M | 1.73M | 1.69M | 1.38M | 1.10M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 246.00K | 246.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.06M | 6.73M | 6.17M | 7.47M | 6.14M | 5.26M | 4.43M | 3.71M | 3.55M | 2.79M | 2.00M | 4.61M | 3.17M | 4.12M | 3.96M | 4.83M | 2.99M | 1.63M | 944.81K | 971.94K | 2.34M | 2.16M | 3.97M | 2.60M | 1.77M | 1.73M | 1.69M | 1.38M | 1.10M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Other Expenses | 0.00 | -74.00K | -55.00K | -137.00K | -218.00K | 73.00K | 71.13K | 13.74K | 10.92K | 10.92K | 10.92K | 5.43K | 7.87K | 9.56K | 1.12M | 1.11M | 738.14K | 0.00 | 0.00 | 0.00 | 8.55K | -661.87K | 3.45M | 268.46K | -1.32M | 258.13K | 186.53K | 189.35K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.34M | 7.98M | 7.48M | 8.67M | 7.39M | 6.88M | 6.09M | 5.11M | 4.25M | 3.45M | 2.76M | 4.74M | 3.27M | 4.23M | 5.25M | 6.05M | 3.86M | 1.76M | 944.81K | 971.94K | 2.35M | 1.50M | 7.42M | 2.86M | 453.95K | 1.99M | 1.87M | 1.57M | 1.20M | 1.40M | 1.60M | 1.60M | 1.10M | 500.00K |
| Cost & Expenses | 16.42M | 11.00M | 8.91M | 9.88M | 8.34M | 7.62M | 6.41M | 5.22M | 4.31M | 3.50M | 2.79M | 4.78M | 3.32M | 4.36M | 5.36M | 6.05M | 3.86M | 1.76M | 944.81K | 971.94K | 2.37M | 1.50M | 7.54M | 2.98M | 476.36K | 1.99M | 1.87M | 1.57M | 1.20M | 6.50M | 8.00M | 9.40M | 8.80M | 5.70M |
| Interest Income | 0.00 | 53.00K | 234.00K | 1.92M | 4.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 135.53K | 35.96K | 0.00 | 153.51K | 0.00 | 255.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 91.00K | 53.00K | 234.00K | 1.92M | 4.00M | 3.49M | 3.86M | 3.13M | 994.67K | 348.15K | 281.59K | 616.35K | 793.26K | 1.67M | 1.63M | 1.15M | 1.56M | 344.88K | 242.49K | 250.70K | 344.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 45.00K | 20.00K | 58.00K | 65.00K | 50.00K | 29.84K | 15.89K | 10.92K | 10.92K | 10.92K | 5.43K | 7.87K | 9.56K | 1.12M | 1.11M | 738.14K | -796.55K | 246.10K | -4.60K | 660.30K | 9.94K | 176.10K | 268.46K | 197.19K | 258.13K | 186.53K | 189.35K | -100.00K | -300.00K | -100.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -4.19M | -5.10M | -6.70M | -7.83M | -7.44M | -7.23M | -5.73M | -4.93M | -4.07M | -3.38M | -2.61M | -4.71M | -3.15M | -4.19M | -4.11M | -5.00M | -3.05M | -2.56M | -698.70K | -967.34K | -1.71M | -1.54M | -2.77M | -4.46M | 1.60M | 664.46K | 245.16K | 1.12M | -100.00K | -2.30M | -400.00K | -200.00K | 1.00M | 1.00M |
| EBITDA Ratio | -34.23% | -85.16% | -248.83% | -299.22% | -341.21% | -449.49% | -1,136.19% | -1,749.86% | -3,346.62% | -3,030.56% | -1,553.32% | -7,189.59% | -2,018.88% | -2,751.20% | 3,370.18% | 0.00% | -3,918.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -881.77% | -225.65% | 246.39% | 27.78% | 12.68% | 44.96% | -7.69% | -51.11% | -5.19% | -2.13% | 10.20% | 14.93% |
| Operating Income | -4.19M | -5.12M | -6.38M | -7.45M | -6.48M | -6.41M | -5.90M | -4.93M | -4.18M | -3.39M | -2.62M | -4.72M | -3.16M | -4.20M | -14.01M | -6.05M | -3.78M | -1.76M | -944.81K | -971.94K | -2.37M | -1.50M | -6.79M | -2.15M | -112.29K | 406.32K | 58.63K | 935.07K | 100.00K | -2.00M | -300.00K | -200.00K | 1.00M | 1.00M |
| Operating Income Ratio | -34.23% | -87.00% | -252.11% | -306.17% | -348.09% | -470.09% | -1,141.98% | -1,755.52% | -3,277.49% | -3,040.35% | -1,559.82% | -7,197.88% | -2,023.91% | -2,678.33% | -10,138.78% | 0.00% | -4,730.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -905.25% | -257.85% | -5.98% | 16.99% | 3.03% | 37.39% | 7.69% | -44.44% | -3.90% | -2.13% | 10.20% | 14.93% |
| Total Other Income/Expenses | -449.00K | 61.00K | -458.00K | -2.12M | -4.74M | -4.28M | -3.65M | -3.14M | -895.55K | -348.15K | -281.59K | -616.35K | -793.26K | -1.54M | -8.76M | 59.99K | -1.48M | 796.55K | -246.10K | -246.10K | -344.83K | 6.74K | 121.94K | 35.96K | -1.41M | 153.51K | 222.88K | 255.93K | 200.00K | 200.00K | 100.00K | 300.00K | 0.00 | -1.00M |
| Income Before Tax | -4.64M | -5.13M | -6.89M | -9.70M | -11.44M | -10.70M | -9.55M | -8.07M | -5.08M | -3.74M | -2.90M | -5.33M | 0.00 | -4.07M | -22.77M | -5.99M | -5.26M | -965.82K | -1.19M | -1.22M | -2.71M | -1.49M | -6.65M | -2.11M | -1.52M | 559.83K | 281.51K | 1.19M | 300.00K | -1.80M | -200.00K | 300.00K | 0.00 | 0.00 |
| Income Before Tax Ratio | -37.90% | -87.22% | -272.38% | -398.85% | -614.72% | -784.16% | -1,849.34% | -2,872.35% | -3,979.42% | -3,352.46% | -1,727.49% | -8,138.27% | 0.00% | -2,599.36% | -16,482.26% | 0.00% | -6,574.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -887.18% | -253.54% | -80.78% | 23.40% | 14.56% | 47.62% | 23.08% | -40.00% | -2.60% | 3.19% | 0.00% | 0.00% |
| Income Tax Expense | 13.00K | -636.00K | 483.00K | 766.00K | 3.31M | -790.00K | 3.43M | 2.89M | 874.50K | -47.45K | -372.92K | 0.00 | 793.26K | 1.54M | 10.39M | 1.09M | 1.48M | 344.88K | -3.61K | 250.70K | 4.91M | 3.44M | 0.00 | 3.47K | -11.54K | 196.71K | 103.68K | 554.64K | -100.00K | -100.00K | -100.00K | 100.00K | -1.00M | -900.00K |
| Net Income | -3.50M | -4.50M | -7.38M | -10.47M | -14.75M | -10.22M | -9.12M | -7.84M | -5.06M | -3.69M | -2.53M | -5.33M | -3.95M | -5.74M | -15.61M | -7.14M | -5.26M | -1.31M | -1.19M | -1.22M | -7.62M | -4.94M | -6.65M | -2.12M | -1.51M | 531.12K | 261.83K | 968.36K | -300.00K | -1.70M | -100.00K | 200.00K | 1.00M | 900.00K |
| Net Income Ratio | -28.65% | -76.41% | -291.47% | -430.35% | -792.53% | -749.34% | -1,766.19% | -2,788.89% | -3,962.92% | -3,309.92% | -1,505.44% | -8,138.27% | -2,531.80% | -3,663.12% | -11,302.54% | 0.00% | -6,574.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -887.18% | -253.96% | -80.16% | 22.20% | 13.54% | 38.72% | -23.08% | -37.78% | -1.30% | 2.13% | 10.20% | 13.43% |
| EPS | -0.01 | -0.02 | -0.03 | -0.05 | -0.10 | -0.08 | -0.09 | -0.09 | -0.06 | -0.05 | -0.03 | -0.08 | -0.07 | -0.13 | -0.37 | -0.17 | -0.18 | -0.48 | -0.55 | -0.66 | -6.25 | -12.61 | -39.08 | -15.72 | -11.43 | 4.00 | 2.27 | 7.25 | -2.27 | -12.88 | -0.76 | 1.52 | 7.58 | 6.82 |
| EPS Diluted | -0.01 | -0.02 | -0.03 | -0.05 | -0.10 | -0.08 | -0.09 | -0.09 | -0.06 | -0.05 | -0.03 | -0.08 | -0.07 | -0.13 | -0.37 | -0.17 | -0.18 | -0.48 | -0.55 | -0.66 | -6.25 | -12.61 | -39.08 | -15.72 | -11.43 | 4.00 | 2.27 | 7.25 | -2.27 | -12.88 | -0.76 | 1.52 | 7.58 | 6.82 |
| Weighted Avg Shares Out | 285.96M | 268.30M | 247.20M | 195.99M | 152.09M | 122.00M | 98.94M | 87.94M | 84.11M | 80.02M | 72.95M | 63.75M | 55.71M | 45.82M | 42.66M | 41.62M | 28.79M | 2.74M | 2.16M | 1.84M | 1.22M | 391.66K | 170.24K | 134.69K | 131.84K | 131.84K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K |
| Weighted Avg Shares Out (Dil) | 285.96M | 268.30M | 247.20M | 195.99M | 152.09M | 122.00M | 98.94M | 87.94M | 84.11M | 80.02M | 72.95M | 63.75M | 55.71M | 45.82M | 42.66M | 41.62M | 28.79M | 2.74M | 2.16M | 1.84M | 1.22M | 391.66K | 170.24K | 134.69K | 131.84K | 131.84K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K | 132.00K |
BioLargo Subsidiary Clyra Medical Selects Keystone Industries to Support Manufacturing of its Medical Products
WESTMINSTER, CA / ACCESSWIRE / June 12, 2024 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its subsidiary Clyra Medical Technologies, Inc. ("Clyra") has selected Keystone Industries,...
BioLargo Manufactures First Cellinity Battery Cells, a Safer Alternative to Lithium-ion
WESTMINSTER, CA / ACCESSWIRE / June 11, 2024 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that it had succeeded in manufacturing its first CellinityTM "Liquid Sodium" prototype...
BioLargo Engineering Secures Multi-Year Air Force Base Air Compliance Project
WESTMINSTER, CA / ACCESSWIRE / June 7, 2024 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its engineering subsidiary has been awarded a contract to provide air...
BioLargo Generates Positive Operating Cash Flow on Record Quarterly Revenues for First Quarter of 2024
WESTMINSTER, CA / ACCESSWIRE / May 14, 2024 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that the company generated $481,000 operating cash flow with record quarterly revenues...
BioLargo Q1 2024 Earnings Results Webcast and Conference Call on Tuesday, May 14, 2024 - 5:30 PM Eastern Time
WESTMINSTER, CA / ACCESSWIRE / May 10, 2024 / BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced it will host an investor webcast and conference call on Tuesday, May...
EPA Adds PFAS to CERCLA (Superfund) Law, Favoring Low-Waste Systems like BioLargo's AEC
BioLargo's PFAS treatment technology generates a fraction of the waste compared to carbon filtration WESTMINSTER, CA / ACCESSWIRE / April 23, 2024 / BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech...
BioLargo PFAS Removal Technology Meets New US Drinking Water Standards
BioLargo's Aqueous Electrostatic Concentrator generates a fraction of the waste product of competing technologies WESTMINSTER, CA / ACCESSWIRE / April 15, 2024 / BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech...
BioLargo Achieved 108% Year-Over-Year Revenue Growth in 2023
WESTMINSTER, CA / ACCESSWIRE / April 2, 2024 / BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its Annual Report, filed April 1, 2024, showed the company's annual...
BioLargo Year-End 2023 Earnings Results Webcast and Conference Call on Tuesday, April 2, 2024 – 5:00 PM Eastern Time
WESTMINSTER, CA / ACCESSWIRE / April 1, 2024 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Tuesday, April 2, 2024, at 2:00 pm...
BioLargo to Present at The LD Micro Invitational XIV
Westminster, California--(Newsfile Corp. - March 25, 2024) - BioLargo, Inc. (OTCQB: BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced today that it will be presenting at the 14th annual LD Micro...
Source: https://incomestatements.info
Category: Stock Reports